Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Manav Salwan

Internal Medicine Sycamore, IL Medical Doctor

NPI 1457424301 CMS profile 293128

2540 Hauser Ross Dr, Suite 275, Sycamore, IL 60178

Open in the dashboard

General payments

$9,753

557 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Manav Salwan of Sycamore, IL is reported in the CMS Open Payments database as having received $9,753 across 557 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,801 90
2024 General $1,638 85
2023 General $1,262 72
2022 General $1,017 63
2021 General $1,317 84
2020 General $1,530 85
2019 General $1,187 78

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Manav Salwan
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Manav Salwan were reported at $1,801. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Manav Salwan Internal Medicine median Middle half National median
2019 $1,187 $159 $48–$570 $163
2020 $1,530 $119 $33–$402 $114
2021 $1,317 $135 $37–$521 $132
2022 $1,017 $141 $42–$496 $149
2023 $1,262 $149 $45–$519 $160
2024 $1,638 $154 $47–$537 $164
2025 $1,801 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,604 82 payments
  2. Novo Nordisk Inc $1,182 74 payments
  3. Lilly USA, LLC $843 50 payments
  4. Amgen Inc. $746 44 payments
  5. Amarin Pharma Inc. $654 31 payments
  6. GlaxoSmithKline, LLC. $529 31 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $514 31 payments
  8. Astellas Pharma US Inc $402 22 payments
  9. Pfizer Inc. $400 21 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $287 16 payments
  11. Other $2,591 155 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,517 547 payments
  2. Education $236 10 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $830 42 payments
  2. Ozempic $717 44 payments
  3. RYBELSUS $579 36 payments
  4. Otezla $491 30 payments
  5. Vascepa $477 21 payments
  6. TRELEGY ELLIPTA $435 24 payments
  7. Repatha $421 26 payments
  8. MOUNJARO $389 20 payments
  9. JARDIANCE Diabetes $326 21 payments
  10. JARDIANCE Diabetes $294 19 payments
  11. Other $7,835 448 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 180 drugs

Part D claims

12,288

Median for Internal Medicine: 777

Drug cost

$1,201,958

Median for Internal Medicine: $73,373

Branded share of claims

22.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 197 $245,429
Eliquis Apixaban Brand 257 $176,488
Otezla Apremilast Brand 24 $112,324
Jardiance Empagliflozin Brand 83 $82,410
Mounjaro Tirzepatide Brand 74 $79,611
Januvia Sitagliptin Phosphate Brand 40 $45,351
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 53 $43,631
Trulicity Dulaglutide Brand 28 $35,126
Tradjenta Linagliptin Brand 38 $28,554
Myrbetriq Mirabegron Brand 48 $27,990

The 10 drugs with the highest cost, of 180 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$402,801

Of which drugs: $49,446

Medicare patients

553

Average age 75

Services billed

6,553

268 women, 285 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 46%
Chronic kidney disease 36%
Ischemic heart disease 34%
Depression 33%
Atrial fibrillation 30%
Heart failure 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 113 113 $32,941
Vaccine for influenza for injection into muscle 90662 Office 142 145 $11,814
Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older 90732 Office 24 24 $3,139
Influenza vaccine, trivalent derived from cell cultures 90661 Office 15 15 $542
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 140 505 $459
Vaccine for tetanus, diphtheria toxoids and acellular pertussis (whooping cough) for injection into muscle, patient 7 years or older 90715 Office 16 16 $441

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
$110 — —
TRELEGY ELLIPTA
$96 53 —
JARDIANCE
$95 83 —
MOUNJARO
$85 74 —
VOQUEZNA
$68 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

557 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record